The primary uses of<unk>  are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease. Gastroesophageal reflux disease Gastroesophageal reflux disease (GERD) is a condition in which the digestive acid in the stomach comes in contact with the esophagus. The irritation caused by this disorder is known as heartburn. Long-term contact between gastric acids and the esophagus can cause permanent damage to the esophagus.<unk>  reduces the production of digestive acids, thus reducing their effect on the esophagus. Duodenal ulcers<unk>  is combined with the antibiotics clarithromycin and amoxicillin (or metronidazole instead of amoxicillin in penicillin-hypersensitive patients) in a 10-day eradication triple therapy for Helicobacter pylori. Infection by H. pylori is a causative factor in the majority of peptic and duodenal ulcers. Efficacy A 2006 meta analysis concluded that compared to other proton pump inhibitors,<unk>  confers a modest overall benefit in esophageal healing and symptom relief. When broken down by disease severity, the benefit of<unk>  relative to other proton pump inhibitors was negligible in people with mild disease (number needed to treat 50), but appeared more in those with severe disease (number needed to treat 8). A second meta analysis also found increases in erosive esophageal healing (>95% healing rate) when compared to standardized doses in broadly selected patient populations. A 2017 study found<unk>  to be among a number of effective doses of PPIs.
Esomeprazole
Rabeprazole
Omeprazole
Lansoprazole
Dexlansoprazole
Tenatoprazole
Pantoprazole
Cimetidine